Atomwise vs Hippocratic AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Atomwise employs 75 people, while Hippocratic AI has 50-200 employees.

Atomwise has raised more in total funding at $219M, compared to Hippocratic AI's $120M — a gap of $99M. Combined, the two companies have completed 5 known funding rounds.

Hippocratic AI holds the higher Awaira Score at 65/100, compared to Atomwise's 53/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 12-point gap that reflects meaningful differences in scale or traction.

Atomwise was founded by Abraham Heifets in 2012. Hippocratic AI was founded by Munjal Shah in 2023. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Hippocratic AI: Hippocratic AI develops a safety-focused AI platform designed to address the global shortage of healthcare professionals by deploying AI agents that perform patient-facing healthcare communication tasks including care navigation, medication adherence outreach, chronic disease monitoring, and post-discharge follow-up. The platform is built around a healthcare-specific large language model with extensive safety evaluation against clinical benchmarks.\n\nThe company raised approximately 120 million USD in early rounds and has established partnerships with health systems and payers focused on reducing care gaps and improving patient engagement at scale. Hippocratic positions its AI as augmenting the healthcare workforce rather than replacing clinicians, targeting the vast volume of lower-acuity patient interactions that do not require physician judgment.\n\nThe healthcare staffing shortage is a structural problem projected to worsen over the next decade, creating durable demand for AI solutions that extend the capacity of existing clinical teams. Hippocratic AI competes with ambient clinical AI companies and general-purpose AI assistant platforms, but its narrow vertical focus on patient-facing healthcare communication and its safety-first design philosophy position it to navigate the regulatory and liability landscape that general AI platforms are less equipped to manage.

Atomwise was founded first in 2012, giving it 11 years of additional market experience. Hippocratic AI was founded later in 2023. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Atomwise has approximately 75 employees, while Hippocratic AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Atomwise and Hippocratic AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.